Mostrar o rexistro simple do ítem

dc.contributor.authorBobadilla-Pérez, Eva
dc.contributor.authorCid-Silva, Purificación
dc.contributor.authorRodríguez‐Sotelo, Alejandro
dc.contributor.authorYáñez‐Rubal, Juan C.
dc.contributor.authorMena, Álvaro
dc.contributor.authorSuárez-López, Francisco
dc.contributor.authorPrieto‐Pérez, Andrea
dc.contributor.authorGiménez‐Arufe, Víctor
dc.contributor.authorDelgado, Manuel
dc.contributor.authorSanclaudio‐Luhia, Ana I.
dc.contributor.authorMartín‐Herranz, Isabel
dc.contributor.authorCastro-Iglesias, Ángeles
dc.contributor.authorMargusino-Framiñán, Luis
dc.date.accessioned2020-04-20T09:16:44Z
dc.date.issued2020-03-17
dc.identifier.citationMargusino‐Framiñán L, Bobadilla‐Pérez E, Cid‐Silva P, et al. Effectiveness and safety of direct‐acting antivirals in hepatitis C infected patients with mental disorders: results in real clinical practice. J Med Virol. 2020es_ES
dc.identifier.issn0146-6615
dc.identifier.issn1096-9071
dc.identifier.urihttp://hdl.handle.net/2183/25372
dc.description.abstract[Abstract] The aim of this study is to analyze the effectiveness and safety of direct‐acting antivirals (DAAs) in psychiatric patients with chronic hepatitis C (CHC). Secondary objectives included adherence and drug‐drug interaction (DDIs) evaluations. Prospective observational comparative study carried out during 3 years. Psychiatric patients were included and mental illness classified by a psychiatric team based on clinical records. Main effectiveness and safety variables were sustained virologic response (SVR) at posttreatment week 12 (SVR12) and rate of on‐treatment serious drug‐related adverse events (AEs), respectively. A total of 242 psychiatric and 900 nonpsychiatric patients were included. SVR12 by intention‐to‐treat (ITT) analysis of psychiatric vs nonpsychiatric patients was 92.6% (95% confidence interval [CI], 89.1‐96.1) vs 96.2% (95% CI, 94.9‐97.5) (P = .02). SVR12 by modified‐ITT analysis was 97.8% (95% CI, 95.0‐99.3) vs 98.4% (95% CI, 97.5‐99.3) (P = .74). 92.2% of psychiatric patients with mental disorders secondary to multiple drug use (MDSDU) and 93.0% of psychiatric patients without MDSDU vs 96.2% of nonpsychiatric patients reached SVR12 (P = .05 and P = .20, respectively). The percentage of adherent patients to DAAs did not show differences between cohorts (P = .08). 30.2% of psychiatric patients and 27.6% of nonpsychiatric patients presented clinically relevant DDIs (P = .47). 1.7% vs 0.8% of psychiatric vs nonpsychiatric patients developed serious AEs (P = .39); no serious psychiatric AEs were present. DAAs have shown a slightly lower effectiveness in psychiatric patients with CHC, as a result of loss of follow up, which justifies the need for integrated and multidisciplinary health care teams. DAAs safety, adherence, and DDIs, however, are similar to that of nonpsychiatric patients.es_ES
dc.language.isoenges_ES
dc.publisherWilley Online Libraryes_ES
dc.relation.urihttps://doi.org/10.1002/jmv.25772es_ES
dc.rightsThis is the peer reviewed version of the article which has been published in final form at Wiley Online Library. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for self-archving.es_ES
dc.subjectChronic hepatitis Ces_ES
dc.subjectClinical researches_ES
dc.subjectComparative effectiveness researches_ES
dc.subjectDirect‐acting antiviralses_ES
dc.subjectDrug safetyes_ES
dc.subjectMental disorderes_ES
dc.titleEffectiveness and Safety of Direct‐Acting Antivirals in Hepatitis C Infected Patients With Mental Disorders: Results in Real Clinical Practicees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessinfo:eu-repo/semantics/embargoedAccesses_ES
dc.date.embargoEndDate2021-03-17es_ES
dc.date.embargoLift2021-03-17
UDC.journalTitleJournal of Medical Virologyes_ES


Ficheiros no ítem

Thumbnail

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem